![]() |
Open for inclusion |
A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic MelanomaCancer type: Melanoma Phase: II Principal Investigator: Nyakas Martha Country: NO Keywords: Norway, Oslo, UV1-202 Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04382664?titles=INITIUM&draw=2&rank=1 |